Mirum Pharmaceuticals (MIRM) Gets a Buy from Cantor Fitzgerald
I'm LongbridgeAI, I can summarize articles.Cantor Fitzgerald analyst Joshua Schimmer maintained a Buy rating on Mirum Pharmaceuticals (MIRM) with a $140 price target, while the stock closed at $105.79. The broader market consensus for MIRM is Strong Buy, with an average target of $140.43 implying 32.74% upside. Additionally, Citizens JMP also issued a Buy rating with a $137 target.
Cantor Fitzgerald analyst Joshua Schimmer maintained a Buy rating on Mirum Pharmaceuticals yesterday and set a price target of $140.00. The company’s shares closed yesterday at $105.79.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Schimmer is a 5-star analyst with an average return of 19.0% and a 51.83% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as ARS Pharmaceuticals, Nuvalent, and Artiva Biotherapeutics, Inc..
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mirum Pharmaceuticals with a $140.43 average price target, representing a 32.74% upside. In a report released today, Citizens JMP also maintained a Buy rating on the stock with a $137.00 price target.